Innovating Works

LIV

Desconocido
AIOIA: AI Organoid Image Analysis LEIBNIZINSTITUT FUR VIROLOGIE tramitó un HORIZON EUROPE: ERC-2023-POC Organoids are microscopically small patient-derived 3D organs that can be cultivated in the laboratory over months mimicking human organs an...
2023-05-22 - 2024-11-30 | Financiado
HORUS: Casting light on HOst-cytomegaloviRUs interaction in Solid organ transplantation LEIBNIZINSTITUT FUR VIROLOGIE participó en un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 "Solid organ transplantation (SOT) is the treatment of choice for end-stage organ failure but the immunosuppressive drugs used to prevent gr...
2022-05-30 - 2027-10-31 | Financiado
ARIADNE: Redefining mass spectrometry a breakthrough platform for real time noninvasive breath analysis wit... LEIBNIZINSTITUT FUR VIROLOGIE participó en un H2020: H2020-FETOPEN-2018-2020 The extraordinary ability of the coronavirus to spread in the environment has established the Covid-19 pandemic as the biggest challenge hum...
2021-03-09 - 2025-05-31 | Financiado
RegNK: Regulation of NK cell function LEIBNIZINSTITUT FUR VIROLOGIE tramitó un H2020: ERC-2019-ADG The human immune system has evolved sophisticated mechanisms to recognize and eliminate infected, stressed or cancer cells. Presentation of...
2020-05-19 - 2025-11-30 | Financiado
MS SPIDOC: Mass Spectrometry for Single Particle Imaging of Dipole Oriented protein Complexes LEIBNIZINSTITUT FUR VIROLOGIE tramitó un H2020: H2020-FETOPEN-2016-2017 The European XFEL has just entered user operation. With its unparalleled peak brilliance and repetition rate, European XFEL has the potentia...
2018-05-25 - 2023-06-30 | Financiado
SPOCkS MS: Sampling Protein cOmplex Conformational Space with native top down Mass Spectrometry LEIBNIZINSTITUT FUR VIROLOGIE tramitó un H2020: ERC-2017-STG The main question to be addressed by SPOCk’S MS is how protein complex conformation adapts to local changes, such as processing of polyprote...
2017-10-04 - 2024-09-30 | Financiado
PEVIA: PAN EBOLA VACCINE INNOVATIVE APPROACH Sofia ref. 116088 LEIBNIZINSTITUT FUR VIROLOGIE participó en un H2020: H2020-JTI-IMI2-2015-08-single-stage Ebola virus (EBOV), a member of Filoviridae family of viruses, is one of the most dangerous microorganisms in the world, causing severe hemo...
2017-05-31 - 2023-05-31 | Financiado
VIRUSCAN: Optomechanics for Virology LEIBNIZINSTITUT FUR VIROLOGIE participó en un H2020: H2020-FETPROACT-2016-2017 Viral infections diagnosis demands novel, cheaper and rapid technologies to overcome present constraints. Current gold standard for diagnosi...
2016-10-13 - 2022-04-30 | Financiado
EBOPATH: Evaluation of species specific ebolavirus pathophysiology in xenochimeric mice LEIBNIZINSTITUT FUR VIROLOGIE participó en un H2020: H2020-MSCA-IF-2015 Ebolaviruses comprise five virus species of which at least three are highly pathogenic for humans. Other mammalian species such as non-human...
2016-03-09 - 2018-10-31 | Financiado
EHVA: European HIV Vaccine Alliance EHVA a EU platform for the discovery and evaluation of novel prophy... LEIBNIZINSTITUT FUR VIROLOGIE participó en un H2020: H2020-PHC-2014-2015 Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. T...
2015-12-17 - 2023-12-31 | Financiado
HIV-NOPA: Assessment of functional immune responses of HIV infected individuals without protective HLA B allel... LEIBNIZINSTITUT FUR VIROLOGIE tramitó un FP7: Infection with the human immunodeficiency virus (HIV) is eventually fatal in the absence of antiretroviral therapy. However, approximately 0...
Financiado
FLU-PHARM: New drugs targeting influenza virus polymerase LEIBNIZINSTITUT FUR VIROLOGIE participó en un FP7: The 2009 H1N1 pandemic and the ongoing threat of highly pathogenic H5N1 strains have focused attention worldwide on the urgent need for effe...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.